Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Artios, Synnovation and Novartis show mere glimmers of activity.
Alongside full PIK3CA wild-type data, Celcuity sets the bar for gedatolisib's PIK3CA-mutant readout.
